

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tovey Christopher J.</u> _____ (Last) (First) (Middle) SOVEREIGN HOUSE, VISION PARK, HISTON _____ (Street) CAMBRIDGE X0 CB24 9BZ _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2018	3. Issuer Name and Ticker or Trading Symbol GW PHARMACEUTICALS PLC [GWPH]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Operating Officer	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares ⁽¹⁾	2,503	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options ⁽²⁾	06/24/2019	06/24/2025	Ordinary Shares	3,930	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	06/24/2018	06/24/2025	Ordinary Shares	7	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	06/24/2018	06/24/2025	Ordinary Shares	27,924	8.7364 ⁽³⁾	D	
Stock Options ⁽²⁾	02/15/2019	02/15/2026	Ordinary Shares	10,457	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/15/2020	02/15/2026	Ordinary Shares	10,457	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/15/2019	02/15/2026	Ordinary Shares	139,420	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/15/2019	02/15/2026	Ordinary Shares	73,508	3.3461 ⁽³⁾	D	
Stock Options ⁽²⁾	01/06/2019	01/06/2027	Ordinary Shares	6,468	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	01/06/2020	01/06/2027	Ordinary Shares	6,468	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	01/06/2021	01/06/2027	Ordinary Shares	6,468	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	01/06/2020	01/06/2027	Ordinary Shares	86,244	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾⁽⁴⁾	01/06/2020	01/06/2027	Ordinary Shares	52,560	9.8117	D	
Stock Options ⁽²⁾	02/26/2019	02/26/2028	Ordinary Shares	8,952	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/26/2020	02/26/2028	Ordinary Shares	8,952	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/26/2021	02/26/2028	Ordinary Shares	8,952	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/26/2022	02/26/2028	Ordinary Shares	8,952	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾	02/26/2021	02/26/2028	Ordinary Shares	119,340	0.0013 ⁽³⁾	D	
Stock Options ⁽²⁾⁽⁴⁾	02/26/2021	02/26/2028	Ordinary Shares	58,884	9.6092	D	

Explanation of Responses:

1. 2,496 of these ordinary shares are represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.
2. Granted pursuant to the Issuer's Long-Term Incentive Plan.
3. Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.302 U.S. Dollars as of September 28, 2018.
4. The reported options are options to purchase ADSs.

Remarks:

/s/ Christopher J. Tovey

10/01/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.